Synthetic Biologics Inc (NYSEMKT:SYN) has been given a consensus recommendation of “Hold” by the six ratings firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $3.92.

Several research firms have recently weighed in on SYN. Zacks Investment Research upgraded Synthetic Biologics from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a research report on Wednesday, August 9th. ValuEngine raised Synthetic Biologics from a “strong sell” rating to a “sell” rating in a report on Friday, August 18th.

Shares of Synthetic Biologics (SYN) opened at 0.9819 on Friday. The company’s market cap is $125.93 million. The firm has a 50-day moving average price of $0.67 and a 200-day moving average price of $0.61. Synthetic Biologics has a 1-year low of $0.41 and a 1-year high of $1.90.

Synthetic Biologics (NYSEMKT:SYN) last released its earnings results on Thursday, August 3rd. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.03. On average, equities analysts expect that Synthetic Biologics will post ($0.17) EPS for the current year.

A number of hedge funds have recently bought and sold shares of SYN. Creative Planning increased its stake in Synthetic Biologics by 65.4% during the second quarter. Creative Planning now owns 177,000 shares of the company’s stock worth $100,000 after acquiring an additional 70,000 shares during the last quarter. Susquehanna International Group LLP grew its stake in shares of Synthetic Biologics by 76.4% in the second quarter. Susquehanna International Group LLP now owns 189,342 shares of the company’s stock valued at $107,000 after buying an additional 82,030 shares in the last quarter. UBS Group AG grew its stake in shares of Synthetic Biologics by 10.3% in the first quarter. UBS Group AG now owns 214,357 shares of the company’s stock valued at $135,000 after buying an additional 20,038 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Synthetic Biologics by 3.1% in the first quarter. Bank of New York Mellon Corp now owns 263,598 shares of the company’s stock valued at $166,000 after buying an additional 7,962 shares in the last quarter. Finally, LMR Partners LLP acquired a new stake in shares of Synthetic Biologics in the second quarter valued at $194,000.

WARNING: This piece was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/23/synthetic-biologics-inc-syn-receives-average-rating-of-hold-from-analysts.html.

About Synthetic Biologics

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.